Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with Juvenile Idiopathic Arthritis Authors:
暂无分享,去创建一个
Ashley P Jones | P. Williamson | A. Dick | D. Hughes | C. Plumpton | P. Woo | B. Hardwick | H. Hickey | M. Beresford | Eifiona Wood | A. McKay | Giovanna Culeddu | S. Lacassagne | V. Athimalaipet | Ramanan
[1] A. Dick,et al. Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy , 2017, Pediatric Rheumatology.
[2] A. Denniston,et al. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. , 2017, Health technology assessment.
[3] Ashley P Jones,et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis , 2017, The New England journal of medicine.
[4] İ. Tuğal-Tutkun,et al. Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis , 2016, Turkish journal of ophthalmology.
[5] K. Eames,et al. Measuring Health Utilities in Children and Adolescents: A Systematic Review of the Literature , 2015, PloS one.
[6] J. Brazier,et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. , 2014, Health technology assessment.
[7] Ashley P Jones,et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial) , 2014, Trials.
[8] David Moher,et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, PharmacoEconomics.
[9] R. Edwards,et al. EQ-5D for the assessment of health-related quality of life and resource allocation in children: a systematic methodological review. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[10] Patrick Royston,et al. Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.
[11] Dmitri A. Jdanov,et al. Human Mortality Database , 2019, Encyclopedia of Gerontology and Population Aging.
[12] R. Rosenfeld,et al. Authority , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[13] Jeremy B Sussman,et al. An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials , 2010, BMJ : British Medical Journal.
[14] B. Thiers. Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis , 2009 .
[15] L. Curtis,et al. Unit Costs of Health and Social Care 2016 , 2015 .
[16] I. Foeldvari,et al. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. , 2005, The Journal of rheumatology.
[17] W. Christen,et al. Outcomes of Treatment with Immunomodulatory Therapy in Patients with Corticosteroid-Resistant Juvenile Idiopathic Arthritis-Associated Chronic Iridocyclitis , 2005, Ocular immunology and inflammation.
[18] M. Boyle,et al. Multiattribute and Single‐Attribute Utility Functions for the Health Utilities Index Mark 3 System , 2002, Medical care.
[19] H. Kautiainen,et al. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. , 2001, Ophthalmology.
[20] A. Weiss,et al. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. , 1998, The Journal of pediatrics.